Maryland drug company cuts COO role, to lay off 400

Emergent BioSolutions, a Gaithersburg, Md.-based company that makes multiple vaccines and achieved the first FDA approval for an over-the-counter naloxone nasal spray, plans to reduce operations at three facilities, lay off about 400 workers and cut its COO role. 

In an Aug. 8 news release, the company said it will shrink operations in Baltimore; Rockville, Md.; and Canton, Mass. Before Oct. 7, the Baltimore location will lay off 211 employees and Rockville will lay off 20, according to WARN notices. Massachusetts has not updated its WARN notices dashboard since Aug. 4.

Adam Havey, an executive vice president and COO, is exiting Sept. 30, Emergent said in the release. The biotech said the changes will result in savings of more than $100 million, according to an Aug. 8 news release.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars